Functional significance of Wnt inhibitory factor-1 gene in kidney cancer

Cancer Research

Volumn 69, Issue 22, 2009, Pages 8603-8610

  Kawakami, Kazumori ^a   Hirata, Hiroshi ^a   Yamamura, Soichiro ^a   Kikuno, Nobuyuki ^a   Saini, Sharanjot ^a   Majid, Shahana ^a   Tanaka, Yuichiro ^a   Kawamoto, Ken ^b   Enokida, Hideki ^b   Nakagawa, Masayuki ^b   Dahiya, Rajvir ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BISULFITE; PROTEIN WNT INHIBITORY FACTOR 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; GENE SEQUENCE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; CARCINOMA, RENAL CELL; DNA METHYLATION; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MICE; MICE, NUDE; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TRANSFECTION; WNT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 72249083497     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2534     Document Type: Article

References (33)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Thoenes W, Störkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 1986;181:125-143
3. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14:1837-1851
4. Morin PJ, Sparks AB, Korinek V, et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997;275:1787-1790 (Pubitemid 27136715)
5. Weeraratna AT, Jiang Y, Hostetter G, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002;1:279-288 (Pubitemid 41039152)
6. Uematsu K, He B, You L, et al. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene 2003;22:7218-7221 (Pubitemid 37378553)
7. Lu D, Zhao Y, Tawatao R, et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2004;101:3118-3123 (Pubitemid 38327744)
8. Urakami S, Shiina H, Enokida H, et al. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/β-catenin signaling pathway. Clin Cancer Res 2006;12:383-391 (Pubitemid 43166125)
9. Rubin JS, Barshishat-Kupper M, Feroze-Merzoug F, et al. Secreted WNT antagonists as tumor suppressors: pro and con. Front Biosci 2006;11:2093-2105 (Pubitemid 43822543)
10. Rubin JS, Bottaro DP. Loss of secreted frizzled-related protein-1 expression in renal cell carcinoma reveals a critical tumor suppressor function. Clin Cancer Res 2007;13:4660-4663 (Pubitemid 47294769)
11. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003;116:2627-2634 (Pubitemid 36857216)
12. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000;103:311-320
13. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-1512 (Pubitemid 28425575)
14. Tetsu O, McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398:422-426 (Pubitemid 29180374)
15. Baldewijns MM, van Vlodrop IJ, Schouten LJ, et al. Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta 2008;1785:133-155
16. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002;21:5427-5440 (Pubitemid 34983479)
17. Kawamoto K, Hirata H, Kikuno N, et al. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines. Int J Cancer 2008;123:535-542 (Pubitemid 351898410)
18. Hsieh JC, Kodjabachian L, Rebbert ML, et al. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 1999;398:431-436 (Pubitemid 29180376)
19. Mazieres J, He B, You L, et al. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 2004;64:4717-4720 (Pubitemid 38924512)
20. Ai L, Tao Q, Zhong S, et al. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis 2006;27:1341-1348 (Pubitemid 43985409)
21. Clément G, Guilleret I, He B, et al. Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus. Cancer Sci 2008;99:46-53. (Pubitemid 350239030)
22. Chan SL, Cui Y, van Hasselt A, et al. The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas. Lab Invest 2007;87:644-650 (Pubitemid 46920100)
23. Taniguchi H, Yamamoto H, Hirata T, et al. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 2005;24:7946-7952 (Pubitemid 41715201)
24. Lin YC, You L, Xu Z, et al. Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth. Hum Gene Ther 2007;18:379-386 (Pubitemid 46709349)
25. Liu J, Lam JB, Chow KH, et al. Adiponectin stimulates Wnt inhibitory factor-1 expression through epigenetic regulations involving the transcription factor specificity protein 1. Carcinogenesis 2008;29:2195-2202
26. Kim J, You L, Xu Z, et al. Wnt inhibitory factor inhibits lung cancer cell growth. J Thorac Cardiovasc Surg 2007;133:733-737 (Pubitemid 46274732)
27. Urakami S, Shiina H, Enokida H, et al. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res 2006;12:6989-6997 (Pubitemid 44974494)
28. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002;18:1427-1431 (Pubitemid 35414532)
29. Wissmann C, Wild PJ, Kaiser S, et al. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 2003;201: 204-212 (Pubitemid 37258931)
30. Gumz ML, Zou H, Kreinest PA, et al. Secreted frizzled- related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 2007;13:4740-4749 (Pubitemid 47294780)
31. Ohigashi T, Mizuno R, Nakashima J, et al. Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells. Prostate 2005;62:61-68 (Pubitemid 39614295)
32. Dehner M, Hadjihannas M, Weiske J, et al. Wnt signaling inhibits Forkhead box O3a-induced transcription and apoptosis through up-regulation of serum- and glucocorticoid- inducible kinase 1. J Biol Chem 2008;283: 19201-19210
33. Tapia JC, Torres VA, Rodriguez DA, et al. Casein kinase 2 (CK2) increases survivin expression via enhanced β-catenin-T cell factor/lymphoid enhancer binding factor-dependent transcription. Proc Natl Acad Sci U S A 2006;103:15079-15084